SCHEMBL2014293

SCHEMBL2014293

COCCOc1ccc(-c2ccc3c(c2)C(C)(C)CCC3(C)C)nc1N1CCN(CCCCCO)CC1

nearest known ligand 0.44

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
RARG P13631 11/20 0.44
RARA P10276 3/20 0.44
RARB P10826 3/20 0.44
PDE5A O76074 6/20 0.38
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
HTR1A P08908 1/20 0.35
HTR7 P34969 1/20 0.35
KCNH2 Q12809 1/20 0.35
DRD2 P14416 1/20 0.35
ADRA1A P35348 1/20 0.35
DRD3 P35462 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12633192 0.94 RARG (0.44) RARGRARARARBPDE5ACTSS
SCHEMBL15241245 0.92 RARG (0.45) RARGRARARARBPDE5ACTSS
SCHEMBL2015951 0.82 RARG (0.43) RARGRARARARBPDE5AKCNH2
SCHEMBL2016394 0.80 RARG (0.45) RARGRARARARBPDE5AHTR1A
SCHEMBL12959614 0.79 RARG (0.44) RARGRARARARB
SCHEMBL2016809 0.79 ACHE (0.39) RARGRARARARBHTR1ADRD2
SCHEMBL12632960 0.78 RARA (0.43) RARGRARARARBPDE5AHTR1A
SCHEMBL2015010 0.78 RARG (0.43) RARGRARARARBPDE5AHTR1A
SCHEMBL2012292 0.78 ACHE (0.40) RARGRARARARBHTR1ADRD2
SCHEMBL12632929 0.78 RARA (0.46) RARGRARARARBHTR1AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062015-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2015-06-23 US disclosed
US-9062015-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2015-06-23 US disclosed
US-9062015-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2015-06-23 US disclosed
EP-2513057-B1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2013-09-04 EP disclosed
EP-2513057-A1 SPHINGOSINE KINASE INHIBITORS Merck Patent GmbH (DE) 2012-10-24 EP disclosed
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
WO-2011072791-A1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE SPHK1, SPHK2, S1PR3 RARG 4187/4885RARA 4373/4885RARB 4194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.